Dr Camille DonabellaHair restoration and medicine
MenuClose

Finasteride and androgenetic alopecia

Finasteride may be considered in selected cases of male androgenetic alopecia. The decision requires clear information and discussion of expected benefit, risks and patient preferences.

Defining the goal

Treatment aims in particular to limit progression. Its value cannot be judged from a single photograph: progress, tolerability and follow-up matter. It does not replace assessment of the cause or a long-term plan.

Discussing adverse effects

Sexual and psychiatric adverse effects can occur. Sexual symptoms have been reported to persist after discontinuation. Medical history, possible symptoms and patient information need discussion before prescribing.

European safety information

In 2025, the European Medicines Agency confirmed suicidal thoughts as an adverse effect of finasteride tablets, with unknown frequency. A person taking 1 mg finasteride for hair loss who develops mood changes should stop treatment and seek prompt medical advice. Sexual symptoms should also be reported to the prescriber.

An individual decision

The decision is neither automatic nor the same for everyone. It depends on understanding benefits and risks. Formulation, indication and conditions of use must be checked for the product and country concerned. New symptoms should lead to reassessment.

Recent scientific publications

Selected references consulted on 18 November 2026. Studies concern specific populations and protocols; they do not predict individual outcomes.